ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2021COVID-19

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

Good Flow: 2021 Updates in Vasculitis

Jason Liebowitz, MD, FACR  |  December 6, 2021

During the ACR Convergence 2021 annual Review Course, Peter Merkel, MD, MPH, provided recent updates on vasculitis.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2021

Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed

Mary Beth Nierengarten  |  December 2, 2021

Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2021myositispatient care

From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management

Jason Liebowitz, MD, FACR  |  December 2, 2021

During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositisOther Rheumatic Conditions Tagged with:ACR Convergence 2021myositis

The State of Clinical Science for Pediatric Rheumatology in 2021

Elizabeth Sloan, MD  |  December 2, 2021

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021ClinicalCOVID-19JIAMultisystem Inflammatory Syndrome in Children (MIS-C)PediatricPediatric Rheumatologypolyarticular juvenile idiopathic arthritis (JIA)

Experts Discuss Blood Disorders Commonly Seen in Lupus Patients

Samantha C. Shapiro, MD  |  December 2, 2021

ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLEanemiaAntiphospholipid Antibody Syndrome (APS)immune thrombocytopeniamacrophage activation syndromeneutropeniathrombocytopenia

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

Jason Liebowitz, MD, FACR  |  November 23, 2021

New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)U.S. Food and Drug Administration (FDA)vaccine hesitancy

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR  |  November 23, 2021

The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19interferonMultisystem Inflammatory Syndrome in Children (MIS-C)

Clinical Rheumatology Year in Review 2021

Samantha C. Shapiro, MD  |  November 22, 2021

ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch RheumRheumatoid ArthritisVasculitis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAClinicalClinical researchJAK inhibitorsjakinibsJanus Kinase InhibitorsKnee Osteoarthritis (OA)stepped exercise

  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 47
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences